Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345638 · ClinicalTrials.gov registry record
Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 52
- Enrollment target
NCT06345638: Completed study, sponsored by University of Pennsylvania.
NCT06345638 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 52 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345638 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD). * The study will compare CRP and other biomarkers between females with SCD in the follicular phase of the menstrual cycle and males with SCD. * The study will explore potential sex differences in biomarker changes between females and males with SCD during and following resolution of VOC. * The study will compare neutrophil and platelet adhesion to the endothelium and real time fibrin deposition in the blood.
Primary Outcome
Serum level of hs-CRP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2025-06-17 |
What the finished NCT06345638 record still lists
NCT06345638 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT06345638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06345638 about?
NCT06345638 is a clinical study titled "Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease". This study aims to characterize sex differences in the pathophysiology of vaso-occlusive crises (VOC) occurring among individuals with sickle cell disease (SCD). * The study will compare CRP and other biomarkers between females with SCD in the follicular phase of the menstrual cycle and males with ...
What is the current status of trial NCT06345638?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2024-03-01. Estimated completion is 2025-06-17.
Who is sponsoring clinical trial NCT06345638?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI